Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
98,365,673
-
Total 13F shares
-
40,082,757
-
Share change
-
+17,579,524
-
Total reported value
-
$141,733,596
-
Put/Call ratio
-
27%
-
Price per share
-
$3.53
-
Number of holders
-
66
-
Value change
-
+$62,472,178
-
Number of buys
-
42
-
Number of sells
-
19
Institutional Holders of POSEIDA THERAPEUTICS INC - Common Stock, par value $0.0001 per share (PSTX) as of Q3 2022
As of 30 Sep 2022,
POSEIDA THERAPEUTICS INC - Common Stock, par value $0.0001 per share (PSTX) was held by
66 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
40,082,757 shares.
The largest 10 holders included
FMR LLC, Pentwater Capital Management LP, EcoR1 Capital, LLC, SILVERARC CAPITAL MANAGEMENT, LLC, VANGUARD GROUP INC, Paradigm Biocapital Advisors LP, Cormorant Asset Management, LP, BlackRock Inc., WELLINGTON MANAGEMENT GROUP LLP, and Aisling Capital Management LP.
This page lists
66
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.